Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics, Inc. (TRDA) is a healthcare company (biotechnology) based in the United States. The share price is $5.24, up 4.80% on the day, which values the company at $205.15M. Price as of 17 Nov 2026, 17:30 UTC, from Yahoo Finance.

Key facts

Share price
$5.24+4.80% today
Market value
$205.15M
Funk Score
30/100
Against its own history
Well below its usual priceusual price $7.78
200-week average
$11.8856% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Entrada Therapeutics, Inc. in more detail

TRDA trades at -1.5× next year's expected earnings, 51.6× sales. Measured against its own history, the price is 33% below what its usual multiples would imply ($7.78) — well below its usual price. It sits 56% below its 200-week average of $11.88.

Its Funk Score is 30 out of 100 (financial strength 4.2, profitability 0.3, value 4.6, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold TRDA, including Julian and Felix Baker (0.2% of the portfolio).

Superinvestors holding TRDA

1 of the investors tracked here report a position in their latest 13F filing.

Entrada Therapeutics, Inc. (TRDA): questions and answers

What is Entrada Therapeutics, Inc.'s market cap?

Entrada Therapeutics, Inc. is valued at $205.15M at a share price of $5.24.

Is TRDA overvalued or undervalued?

Against its own history, TRDA is well below its usual price: the price is 33% below the $7.78 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is TRDA above its 200-week moving average?

No. TRDA is 55.9% below its 200-week average of $11.88. Long-term investors watch that line because strong companies rarely trade below it for long.

Does TRDA pay a dividend?

Entrada Therapeutics, Inc. does not currently pay a regular dividend.

Which famous investors own TRDA?

In their latest quarterly filings, Julian and Felix Baker (0.2% of the portfolio) hold TRDA. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Entrada Therapeutics, Inc. (TRDA) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TRDA

Underlying data: Yahoo Finance; company filings with the SEC.